New cancer drug targets key growth protein in advanced tumors
NCT ID NCT05100251
Summary
This was an early-stage study to test the safety and find the right dose of a new drug called WBC100. It involved 68 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to see how much of the drug patients could tolerate and to check for side effects, while also looking for early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.